GH Research PLC (GHRS)
GH Research PLC operates in the Biotechnology industry of the Healthcare sector, headquartered in Dublin, DU, IE. The stock last traded at $30.12, up 3.58% on the session, giving a market capitalisation of $2.06B. On trailing twelve-month figures it carries a trailing P/E of -30.12, a net margin of 0.0%. Its beta of 1.29 implies it has historically moved more than the broad market.
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
GH Research PLC is most often compared with the following Healthcare names: